Aeterna Zentaris (AEZS) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
March 15, 2017 4:48 PM EDTClinical phase of Zoptrex and Macrilen development programs completed; Zoptrex top-line results expected in April
All amounts are in US Dollars
Recent key developments
Development programs progressing toward completion Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 trial clinically completed on January 30, 2017; pre-NDA meeting with FDA held on January 31, 2017; top-line results expected to be reported in April 2017 Company believes that analysis of data from confirmatory Phase 3 trial of Macrilen (macimorelin) is supportive of registration consideration; Meeting with FDA will be held at the end of Q1... More